Please assess the completion status of the following clinical trial:

Trial Title: Intravenous Iron in Gynecologic Cancer Patients Receiving Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 20-70 years~* Good performance status (Zubrod score \< 2)~* No serious underlying disease~* Normal renal function test~* Normal liver function test~* Platinum based chemotherapy is the first line regimen~* No prior or receiving radiotherapy~Exclusion Criteria:~* Iron hypersensitivity~* Underlying disease which has the risk of iron overload such as chronic kidney disease, major thalassemia~* Progressive disease~* Bone marrow metastasis

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Intravenous iron (Type: EXPERIMENTAL): Iron sucrose 200 mg intravenous infusion in 15 minutes
- Oral iron (Type: PLACEBO_COMPARATOR): Ferrous fumarate 200 mg oral three times a day

Based on this trial design, predict the completion outcome and termination type (if applicable).